| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 36 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Obese |
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium.
Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.
